GVR Report cover PEGylated Proteins Market Size, Share & Trends Report

PEGylated Proteins Market Size, Share & Trends Analysis Report By Type (PEGylation kits and reagents), By Product, By Application, By End-user, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453402
  • Number of Pages: 0
  • Format: Electronic (PDF)

PEGylation is the process of a combination of polyethylene glycol (both covalent and non-covalent) polymer chains with molecules, proteins, and peptides. This is useful in targeted drug delivery systems and in genetically modifying cells. These molecules have a long half-life (in the bloodstream), reduced toxicity, decreased immunogenicity, and increased proteolytic protection. Separation of the PEGylated proteins is done using chromatography. It includes such as size exclusion chromatography (SEC), hydrophobic interaction chromatography, and electrostatic interaction chromatography (ion-exchange chromatography, IEC). On the other hand, the process cost of the process is comparatively high. Polyethylene glycol is regarded as safe by US FDA for internal administration.

PEGylation of proteins also has pharmacological advantages and significance which include improved drug solubility, reduced dosage frequency, increased drug stability, and minimum loss of biological activity. Some of FDA approved pegylated drugs are Cimzia, Mircera, Macugen, Somavert, Pegasys, and Neulasta. These drugs are useful to treat various diseases like Crohn’s disease, anemia in chronic kidney disease, age-related macular degeneration, Acromegaly, hepatitis C, and Neutropenia during chemotherapy. PEG molecules in the conjugation of nanoparticles are used in the advanced drug-delivery systems for anti-cancer therapy.

The research on PEGylated protein drugs focuses on adenosine deaminase, asparaginase, interferons, granulocyte colony-stimulating factor, interleukins, etc. Recently JenKem Technology is the large-scale manufacturer of PEG derivatives of lipid nanoparticles and other intermediates. Increased incidence of cancer and delay in the diagnosis is been observed all over the globe as per the research of JCO Clinical Cancer Informatics in the U.S. The awareness among the patients and healthcare professionals is observed for the adverse effects of cancer treatments like chemotherapy. So the major focus for alternative therapeutics treatment like pegylated peptide-based drugs, colony-stimulating factors is the driving factor for the growth of the market in the forecast years.

The PEGylated protein market is segmented based on product type, protein type, application, end-user, and region. On the basis of product type the market is segmented into consumables and services. Consumables include PEGylation kits and PEGylation reagents. Based on the protein type, the market is segmented based on colony-stimulating factor, interferons, erythropoietin, and recombinant factor VII.

North America dominates the markets due to the rise in the prevalence of chronic diseases like cancer. The cancer treatment estimates the highest CAGR during the forecast period. This is due to the increase in the adoption of new drugs for the treatments like monoclonal antibodies, interferons, and many more. Along with this the increase in government funding, and grants for research projects with the advancements in the field of biotechnology and research and development boost the North American PEGylated Protein Market.

                                           PEGylated Proteins Market Segmentation

Segments

Details

Type

Consumables (PEGylation kits and reagents),

Services (Development, production, feasibility study)

Protein

Colony-stimulating factor,

Interferons,

Erythropoietin,

Recombinant factor VII

Other protein types,

Application

Cancer (nanoparticles associated drug delivery system)

Autoimmune Disease (Telerogenic Immunomodulation by PEGylated Antigenic peptides)

Hepatitis (PEGylated interferons)

Multiple Sclerosis (PEGylated interferon beta)

Hemophilia

Gastrointestinal Disorder (Inflammatory bowel disease-PEGylation on antibody loaded NPs)

Others

End user

Pharmaceutical and Biotechnology Companies,

Contract Research Organizations,

Academic Research Institutes

Region

North America (U.S., Canada),

Europe (Germany, UK, France, Italy, Spain),

Asia Pacific (China, Japan, India, Australia, South Korea),

Latin America (Brazil, Mexico, Argentina)

Middle East & Africa (Saudi Arabia, UAE, South Africa)

 

There are several key players and vendors in the market focusing on developing and launching new products and expanding the PEGylated Drug Markets in global and larger markets. These include Thermo Fisher Scientific Inc., Horizon Therapeutics Plc., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., UCB S.A, AstraZeneca, Amgen, Inc., Biogen, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Bayer AG, Coherus Biosciences, Biomarin Pharmaceutical Inc., Enzon, Leadient Biosciences, Inc. Recently Thermo Fisher Scientific Inc., announced their strategic partnership with CSL Limited to help the growing demand for biologic therapies.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.